Leerink Positive on Array BioPharma (ARRY) Following ARRY-797 Phase 2 Update
Tweet Send to a Friend
Leerink affirms Array BioPharma (Nasdaq: ARRY) at Outperform with a price target of $6 after the company announced results from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
